Can fecal microbiota transplantation treat recurrent C. difficile infections?

How well does FMT actually work for recurrent C. difficile?

FMT cures recurrent C. difficile infection (rCDI) in the vast majority of patients. A large meta-analysis of 15 studies including 777 patients with rCDI and inflammatory bowel disease (IBD) found that a single FMT cured 81% of cases, and when repeat FMT was allowed, the overall cure rate rose to 92% [1]. This means that for every 100 patients, roughly 92 will be infection-free after one or two FMT sessions.

Real-world data from a prospective registry of 269 patients (301 FMT procedures) at six centers showed similar results: 86% were cured at one month and 81% at two months, with no difference between capsule and colonoscopy delivery [4]. A separate cohort study of 108 patients reported a 60-day recurrence rate of 20%, which is comparable to earlier clinical trials [3]. These figures are consistently higher than the 50-60% success rates typically seen with standard antibiotic tapers for recurrent disease.

The evidence is clear that FMT is significantly more effective than medical therapy specifically for recurrent (not first-time) C. difficile. A meta-analysis of 7 randomized controlled trials found that FMT had a statistically significant advantage over antibiotics for rCDI (risk ratio 2.41), meaning patients were more than twice as likely to be cured with FMT [8]. However, for a first episode of C. difficile, FMT showed no benefit over standard antibiotics, so it is reserved for recurrent cases.

Does FMT work for patients with IBD, older age, or other complex conditions?

Yes, FMT is effective even in challenging patient groups, though success rates can be slightly lower and require careful management. In patients with IBD (Crohn's disease or ulcerative colitis), a meta-analysis of 777 patients found an 81% cure rate with a single FMT and 92% with repeat FMT [1]. A separate prospective study of 50 IBD patients reported that 62-73% experienced improvement in their IBD symptoms after FMT, and only 4% had a new IBD flare [5]. However, another study of 145 IBD patients found a lower overall cure rate of 80%, with 7.6% experiencing worsening IBD [12]. The key takeaway: FMT works well in IBD patients, but they may need repeat treatments and close monitoring for IBD flares.

For very old and frail patients (median age 88 years), FMT remains safe and effective. A study of 43 patients aged 85+ found a first-FMT success rate of 77%, rising to 88% with repeat FMT [9]. Frailty scores helped predict who might need a second transplant, but even the most frail patients benefited. In a larger registry of 609 patients (median age 56), long-term follow-up (median 3.7 years) showed no increased risk of infections or serious adverse events related to FMT [6].

Certain factors do increase the risk of FMT failure. A nested case-control study of 522 patients identified that use of systemic antibiotics after FMT (odds ratio 7.39), having IBD (odds ratio 4.34), and poor bowel preparation before the procedure (odds ratio 3.84) were strong predictors of failure [13]. Older age and use of immunosuppressant medications were also associated with higher recurrence risk in a separate study [3]. These findings mean that doctors should optimize bowel preparation, avoid unnecessary antibiotics after FMT, and consider repeat FMT for high-risk patients.

What are the risks and other benefits of FMT?

FMT is generally safe, with most side effects being mild and temporary. In a meta-analysis of 777 patients, serious adverse events occurred in 12% of patients, but these were mostly hospitalizations, IBD-related surgery, or IBD flares — not directly caused by the FMT itself [1]. In very old patients (85+), mild adverse events (like bloating or temporary diarrhea) occurred in 25%, with no deaths related to the procedure [9]. A long-term safety study of 609 patients followed for a median of 3.7 years found that new infections or other new diagnoses were rare and not linked to FMT [6].

Beyond curing C. difficile, FMT may offer unexpected benefits. A case-control study of 25 patients found that FMT significantly reduced the frequency of urinary tract infections (UTIs) — from a median of 4 UTIs in the year before FMT to 1 in the year after — and also reduced the proportion of antibiotic-resistant bacteria in urine samples [7]. This suggests that restoring a healthy gut microbiome can help control other infections. Additionally, FMT has been associated with reduced alcohol relapse and improved survival in patients with alcohol-associated hepatitis, though this is a different condition [11].

The delivery method matters less than the treatment itself. Oral capsules are as effective as colonoscopy-delivered FMT, with a meta-analysis of 763 patients showing an 82.1% cure rate for capsules and no serious adverse events attributed to the treatment [10]. A prospective registry confirmed no difference in cure rates between capsule and colonoscopy FMT [4]. This means patients can often choose the less invasive oral option without sacrificing effectiveness.

About These Sources

This answer is built on 13 peer-reviewed studies — published from 2021 to 2026, 2 from 2024 or later, 5 in Q1 journals, collectively cited 316 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 74 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions